editorial memo (2018) 11:84 https://doi.org/10.1007/s12254-018-0417-x Update and clinical highlights presented at the 2017 American Society of Hematology Meeting Daniel Heintel Received: 2 May 2018 / Accepted: 22 May 2018 / Published online: 1 June 2018 © Springer-Verlag GmbH Austria, part of Springer Nature 2018 At the 2017 American Society of Hematology (ASH) rituximab maintenance following R-CHOP induction. meeting partly standards-changing data in the treat- The median PFS was 10.5 vs. 4 years (p < 0.0001). ment of hematological malignancies were presented. Also in mantle cell lymphoma, the superiority of More than 5000 scientiﬁc abstracts are submitted each rituximab maintenance was proven. year and more than 3000 abstracts are accepted for In ﬁt patients with multiple myeloma, eligible for oral and poster presentations through an extensive autologous stem cell transplantation, new induction peer review process. In this issue of memo ﬁve hema- regimens showed high minimal residual disease neg- tologists summarized their personal highlights in their ativity rates. respective areas of expertise. Regarding CML interesting data regarding novel My personal highlight was the presentation of the TKIs or treatment duration of imatinib were pre- MURANO study. The clear superiority of a targeted sented. therapy changes practical behavior with immune- In the treatment of AML novel promising sub- chemotherapy having no place in second-line treat- stances enrich the spectrum of therapy choices which ment of chronic lymphocytic leukemia (CLL) any- also impressed the audience at the last ASH meeting. more. Moreover, the authors summarize important Conﬂict of interest D. Heintel receives honoraria from Abb- data about the combination of venetoclax and ibruti- vie, Celgene, Gilead, Janssen, MSD, Roche, Takeda. nib. In addition to CLL, reviews about important de- velopments in the treatment of indolent lymphoma, 7 For latest news from interna- multiple myeloma, CML, and AML are provided in this tional oncology congresses see: series. http://www.springermedizin.at/ Concerning indolent lymphoma, Dr. Gilles Salles memo-inoncology presented a 10-year update of the PRIMA trial, con- ﬁrming a progression-free survival (PFS) beneﬁt for Dr. D. Heintel () Wilhelminenspital, Montleartstraße 37, 1160 Vienna, Austria firstname.lastname@example.org 84 Update and clinical highlights presented at the 2017 American Society of Hematology Meeting K
memo - Magazine of European Medical Oncology – Springer Journals
Published: Jun 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera